Mdm2 is an oncogene, and UBX0101 was developed to inhibit Mdm2 and target the clearance of senescent synoviocytes.6 However, a phase 2 clinical trial declared that the drug was ineffective.41 Our experiment demonstrates that overexpression of Mdm2 can reverse lopinavir-induced senescence of chondrocytes in vitro; however, it carries safety risks related to cancer formation. Here, MDM2 is linked to cancer.